Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Public ClinicalTrials.gov record NCT00994500. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial is studying the side effects and best dose of vorinostat when given together with bortezomib in treating young patients with refractory or recurrent solid tumors, including CNS tumors and lymphoma. Vorinostat and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Study identification
- NCT ID
- NCT00994500
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 20 participants
Conditions and interventions
Conditions
- Childhood Burkitt Lymphoma
- Childhood Central Nervous System Choriocarcinoma
- Childhood Central Nervous System Germ Cell Tumor
- Childhood Central Nervous System Germinoma
- Childhood Central Nervous System Mixed Germ Cell Tumor
- Childhood Central Nervous System Teratoma
- Childhood Central Nervous System Yolk Sac Tumor
- Childhood Choroid Plexus Tumor
- Childhood Craniopharyngioma
- Childhood Diffuse Large Cell Lymphoma
- Childhood Immunoblastic Large Cell Lymphoma
- Childhood Medulloepithelioma
- Childhood Meningioma
- Childhood Mixed Glioma
- Childhood Nasal Type Extranodal NK/T-cell Lymphoma
- Childhood Oligodendroglioma
- Recurrent Childhood Anaplastic Large Cell Lymphoma
- Recurrent Childhood Brain Stem Glioma
- Recurrent Childhood Central Nervous System Embryonal Tumor
- Recurrent Childhood Cerebellar Astrocytoma
- Recurrent Childhood Cerebral Astrocytoma
- Recurrent Childhood Ependymoma
- Recurrent Childhood Grade III Lymphomatoid Granulomatosis
- Recurrent Childhood Large Cell Lymphoma
- Recurrent Childhood Lymphoblastic Lymphoma
- Recurrent Childhood Malignant Germ Cell Tumor
- Recurrent Childhood Medulloblastoma
- Recurrent Childhood Pineoblastoma
- Recurrent Childhood Small Noncleaved Cell Lymphoma
- Recurrent Childhood Subependymal Giant Cell Astrocytoma
- Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
- Recurrent Childhood Visual Pathway and Hypothalamic Glioma
- Recurrent Childhood Visual Pathway Glioma
- Recurrent/Refractory Childhood Hodgkin Lymphoma
- Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
- vorinostat Drug
- bortezomib Drug
- pharmacological study Other
- laboratory biomarker analysis Other
Drug · Other
Eligibility (public fields only)
- Age range
- 1 Year to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2009
- Primary completion
- Jun 30, 2011
- Completion
- Not listed
- Last update posted
- Jul 1, 2013
Started 2009
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Childrens Memorial Hospital | Chicago | Illinois | 60614 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Children's Hospital of Pittsburgh of UPMC | Pittsburgh | Pennsylvania | 15224 | — |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00994500, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 1, 2013 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00994500 live on ClinicalTrials.gov.